The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic and predictive implications of plasma ctDNA in guiding first-line targeted therapy for metastatic HER2-mutant non-small cell lung cancer (NSCLC).
 
Si-Yang Liu
No Relationships to Disclose
 
Justin Jee
No Relationships to Disclose
 
Fernando Costa Santini
Honoraria - Amgen; Bayer
Consulting or Advisory Role - Bayer; Lilly
Speakers' Bureau - Bayer
 
Adam Jacob Schoenfeld
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Enara Bio; Heat Biologics; Immunocore; Iovance Biotherapeutics; Johnson & Johnson/Janssen; KSQ Therapeutics; Legend Biotech; Lyell Immunopharma; Merck; Oppenheimer; Perceptive Advisors; Prelude Therapeutics; Umoja Biopharma
Research Funding - Achilles Therapeutics; Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Harpoon therapeutics; Instil Bio; Iovance Biotherapeutics; Merck; PACT Pharma
Travel, Accommodations, Expenses - Instil Bio; Iovance Biotherapeutics
Other Relationship - Achilles Therapeutics; Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Harpoon therapeutics; Instil Bio; Iovance Biotherapeutics; Merck; PACT Pharma
 
Jordan Eichholz
No Relationships to Disclose
 
Kaylie Johnson
No Relationships to Disclose
 
Andres Martinez
No Relationships to Disclose
 
Jiannan Guo
Employment - Resolution Bioscience
 
Nadeem Riaz
Honoraria - PeerView
Consulting or Advisory Role - Mirati Therapeutics; Repare Therapeutics
Speakers' Bureau - Illumina
Research Funding - Bristol-Myers Squibb; Paige.AI; Pfizer; Repare Therapeutics
Travel, Accommodations, Expenses - Varian Medical Systems
 
Nancy Y. Lee
Consulting or Advisory Role - Merck; Merck Serono; Mirati Therapeutics; Roche/Genentech
Research Funding - AstraZeneca; Pfizer
 
Luke Roy George Pike
Stock and Other Ownership Interests - Clovis Oncology; Novavax; Schrodinger
Consulting or Advisory Role - Aviko; Best Doctors, Inc; Blackstone; Deerfield Management; Dynamo Therapeutics; Galera Therapeutics; Monograph Capital; Myst Therapeutics; Roivant; Third Rock Ventures; Turnstone Bio
 
Howard I. Scher
Honoraria - Arsenal Capital; Elsevier
Consulting or Advisory Role - AIQ Global; Bayer; Genzyme; Janssen Research & Development; Pfizer; Promontory Therapeutics; Regeneron; WIRB-Copernicus Group
Research Funding - AIQ Solutions (Inst); Biodesix (Inst); Epic Sciences (Inst); Janssen (Inst); Thermofisher Scientific Biomarkers (Inst)
Patents, Royalties, Other Intellectual Property - BioNTech -Intellectual Property Rights; Elucida Oncology - Intellectual Property Rights; MabVAX - Intellectual Property Rights; Y-mAbs Therapeutics, Inc - Intellectual Property Rights
Travel, Accommodations, Expenses - Bayer; Biodesix; Epic Sciences; Promontory Therapeutics; Prostate Cancer Foundation; WIRB-Copernicus Group
 
Alexander E. Drilon
Stock and Other Ownership Interests - Treeline Biosciences
Honoraria - Answers in CME; Associazione Italiana Oncologia Toracica (AIOT); AstraZeneca; BeiGene; Chugai Pharma; Clinical Care Options/NCCN; Helsinn Therapeutics; i3 Health; IASLC; Ignyta/Genentech/Roche; Liberum; Loxo/Bayer/Lilly; Lung Cancer Research Foundation; Lungevity; NIH; OncLive/MJH Life Sciences; PER; Pfizer; Remedica; Remedica; Research to Practice; RV Mais; Sirio Libanes Hospital; TP Therapeutics; Verastem
Consulting or Advisory Role - 14ner Oncology/Elevation Oncology; Abbvie; Amgen; Applied Pharmaceutical Science; Archer; AstraZeneca; Axis Pharma; Bayer; BeiGene; BerGenBio; Blueprint Medicines; Clinical Care Options; Clinical Care Options; EMD Serono/Merck; Entos; EPG Health; Exelixis; Genentech/Roche; Hengrui Therapeutics; Ignyta; Janssen; Journal of the National Comprehensive Cancer Network; Liberum; Lilly; Loxo; Med Learning; Medscape; Melendi; Merus; Monopteros Therapeutics; Monte Rosa Therapeutics; MORE Health; Novartis; Nuvalent, Inc.; Ology Medical Education; Ology Medical Education; PeerView; Pfizer; Prelude Therapeutics; Repare Therapeutics; Takeda/Millennium; touchIME; Treeline Biosciences; Tyra Biosciences
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - Boehringer Ingelheim; GlaxoSmithKline; Merck; Merus; Pfizer; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva
 
Maria E. Arcila
Consulting or Advisory Role - AstraZeneca; Axis Medical Education; Bristol-Myers Squibb; Clinical Education Alliance; Janssen; Physicans' Education Resource; RMEI Medical Education; Roche
 
Jorge S. Reis-Filho
Leadership - Grupo Oncoclinicas
Stock and Other Ownership Interests - PAIGE.AI; Repare Therapeutics
Consulting or Advisory Role - Bain Capital Life Sciences; Genentech/Roche; Goldman Sachs; Invicro; Novartis; Paige.AI; Personalis; Repare Therapeutics; SAGA Diagnostics; Ventana Medical Systems; Volition RX
 
Pedram Razavi
Stock and Other Ownership Interests - Odyssey Biosciences
Honoraria - Daiichi Sankyo/Astra Zeneca; Pfizer
Consulting or Advisory Role - AstraZeneca; bioTheranostics; Epic Sciences; Guardant Health; Guardant Health; Inivata; Natera; Novartis; PAIGE.AI; Prelude Therapeutics; SAGA Diagnostics; Tempus
Research Funding - Archer (Inst); AstraZeneca (Inst); AstraZeneca (Inst); bioTheranostics (Inst); Epic Sciences (Inst); GRAIL (Inst); Guardant Health (Inst); Illumina (Inst); Novartis (Inst); Tempus (Inst)
 
David Randolph Jones
Consulting or Advisory Role - AstraZeneca; Merck
Speakers' Bureau - DAVA Oncology; Genentech/Roche
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bridge Medicines; Daiichi Sankyo/UCB Japan; Earli; Epizyme; Genentech/Roche; Harpoon Therapeutics; Ipsen; Jazz Pharmaceuticals; Kowa; Merck; Syros Pharmaceuticals; Syros Pharmaceuticals
Research Funding - Merck (Inst); Roche/Genentech (Inst)
 
James M. Isbell
Stock and Other Ownership Interests - LumaCyte
 
Bob T. Li
Research Funding - Ambrx (Inst); Amgen (Inst); AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); Hengrui Therapeutics (Inst); Lilly (Inst); MORE Health (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Karger Publishers - Book royalty; Shanghai Jiao Tong University Press - Book royalty; US62/514,661 (Inst); US62/685,057 (Inst)
Travel, Accommodations, Expenses - Jiangsu Hengrui Medicine; MORE Health
(OPTIONAL) Uncompensated Relationships - Amgen; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Genentech; Lilly